TTNP

Titan Pharmaceuticals Stock Price

2.35
0.11 (4.91%)
Upgrade to Real-Time
Afterhours (Closed)
2.35

Low
2.15

52 Week Range

High
14.064

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Titan Pharmaceuticals Inc TTNP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.11 4.91% 2.35 18:00:05
Open Price Low Price High Price Close Price Prev Close
2.28 2.28 2.40 2.35 2.24
Bid Price Ask Price Spread News
2.30 2.37 0.07 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,037 151,830 $ 2.33 $ 353,454 293,196 2.15 - 14.064
Last Trade Time Type Quantity Stock Price Currency
18:44:51 15 $ 2.35 USD

Titan Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 23.18M 9.86M 9.86M $ 4.84M $ - -4.83 -0.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 30.30%

more financials information »

Titan Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TTNP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.462.582.222.36182,472-0.11-4.47%
1 Month2.892.912.152.43273,820-0.54-18.69%
3 Months3.8254.612.153.43862,553-1.48-38.56%
6 Months2.9648.852.155.0513,657,579-0.614-20.72%
1 Year10.8014.0642.156.0913,225,373-8.45-78.24%
3 Years117.00207.002.1514.327,706,670-114.65-97.99%
5 Years907.201,573.202.1525.984,731,240-904.85-99.74%

Titan Pharmaceuticals Description

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.


Your Recent History
NASDAQ
TTNP
Titan Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.